drugset / Trial / NCT01435096
BN80927 in Patients With Advanced Malignant Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study was to determine the maximum tolerated dose and the recommended dose of BN80927 in patients with advanced malignant solid tumors.
Timeline
- Start
- 2004-11
- Primary completion
- 2007-10
- Completion
- 2007-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BN80927 | Unknown | — | Intravenous |